Related Experiment Video

Updated: Jun 5, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer

Celina Ablinger1,2, Daniel Neureiter3,4, Theresa Mähr1

  • 1Institute of Pharmacy, Department of Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria.

Cancer Biology & Therapy
|December 13, 2024
PubMed

Insights

Dinaciclib effectively combats biliary tract cancer (BTC) by reducing cell viability and inducing apoptosis. This cyclin-dependent kinase inhibitor shows promise as a novel anti-cancer therapeutic in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Biliary tract cancer (BTC) is a rare malignancy with limited therapeutic options and poor prognosis.
  • Cyclin-dependent kinases (Cdks) are crucial for cell cycle regulation and are frequently dysregulated in cancers.
  • Dinaciclib is a potent inhibitor of Cdk1/2/5/9 with demonstrated anti-tumor activity.

Purpose of the Study:

  • To evaluate the efficacy of dinaciclib in preclinical biliary tract cancer models.
  • To investigate the molecular mechanisms underlying dinaciclib's anti-tumor effects in BTC.
  • To assess dinaciclib's impact on cell viability, apoptosis, and key signaling pathways in BTC cells.

Main Methods:

  • Utilized a comprehensive panel of 2D and 3D biliary tract cancer cell line models.
  • Assessed dinaciclib's effects on cell viability, ATP levels, proliferation, and apoptosis (caspase 3/7 activity).
  • Analyzed the expression of cell cycle regulators, apoptosis-related proteins (Mcl-1), and signaling pathways (EGFR, STAT3).

Main Results:

  • Dinaciclib significantly reduced cell viability, ATP levels, and proliferation in BTC cell lines.
  • The drug induced apoptosis through increased caspase 3/7 activity and decreased Mcl-1 expression.
  • Dinaciclib demonstrated efficacy in 3D cell cultures, mimicking physiological tumor conditions, and modulated EGFR and STAT3 signaling.

Conclusions:

  • Dinaciclib exhibits significant anti-tumorigenic activity in both 2D and 3D in vitro models of biliary tract cancer.
  • The compound effectively reduces cell viability and induces apoptosis, offering a potential new therapeutic strategy.
  • Further investigation into dinaciclib for BTC treatment is warranted based on these promising preclinical findings.
Keywords:
3D cell cultureCdkapoptosisbiliary tract cancercytotoxicitydinaciclib

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

28.5K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147